PMID- 26523483
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20161126
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 12
IP  - 1
DP  - 2016
TI  - Golimumab for the treatment of axial spondyloarthritis.
PG  - 9-18
LID - 10.1586/1744666X.2016.1106941 [doi]
AB  - Axial spondyloarthritis (axSpA) is a chronic, immune-mediated inflammatory 
      disease of the axial skeleton that includes ankylosing spondylitis (AS) and 
      non-radiographic axial spondyloarthritis (nr-axSpA). Patients with AS experience 
      chronic pain due to sacroiliac joint and spinal inflammation, and may develop 
      spinal ankylosing with syndesmophyte formation. Tumor necrosis factor alpha 
      inhibitors (TNFi) have shown promise in the management of AS and axSpA by 
      targeting the underlying inflammatory process, and providing symptomatic relief. 
      Whether they alter the progression of the disease is uncertain. Golimumab is a 
      fully human IgG1 monoclonal antibody that targets and downregulates the 
      pro-inflammatory cytokine TNF-alpha. The use of golimumab has been shown to reduce 
      the signs and symptoms of axSpA as well as improve patient function and quality 
      reported outcomes. This review focuses on the biological rationale and the 
      results of clinical trials with golimumab for the treatment of axSpA.
FAU - Gelfer, Gita
AU  - Gelfer G
AD  - a Division of Arthritis & Rheumatic Diseases (OP09) , Oregon Health & Science 
      University , Portland , OR 97239 , USA.
FAU - Perry, Lisa
AU  - Perry L
AD  - a Division of Arthritis & Rheumatic Diseases (OP09) , Oregon Health & Science 
      University , Portland , OR 97239 , USA.
FAU - Deodhar, Atul
AU  - Deodhar A
AD  - a Division of Arthritis & Rheumatic Diseases (OP09) , Oregon Health & Science 
      University , Portland , OR 97239 , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151102
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 91X1KLU43E (golimumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Immunotherapy
MH  - Spondylitis, Ankylosing/immunology/*therapy
MH  - Tumor Necrosis Factor-alpha/immunology
OTO - NOTNLM
OT  - Ankylosing spondylitis
OT  - TNF inhibitors
OT  - anti-tumor necrosis factor
OT  - axial spondyloarthritis
OT  - golimumab
OT  - non-radiographic axial spondyloarthritis
EDAT- 2015/11/03 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/11/03 06:00
PHST- 2015/11/03 06:00 [entrez]
PHST- 2015/11/03 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.1586/1744666X.2016.1106941 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2016;12(1):9-18. doi: 10.1586/1744666X.2016.1106941. 
      Epub 2015 Nov 2.